All Pharmaceutical Microbiology articles – Page 3
-
NewsDrug-resistant tuberculosis responds rapidly to bedaquiline-based second-line therapy
Patients who have drug-resistant tuberculosis (TB) have a similar microbiological response to bedaquiline-based second-line medications as patients with drug-sensitive TB taking first-line regimens.
-
NewsSpace-grown antiviral drug successfully brought back to earth in private Varda Space capsule
Space-grown crystals of an antiviral drug have been brought to earth following the successful recovery of the capsule from Varda Space Industries’ W-1 mission.
-
NewsResearchers develop molecules for a new class of antibiotics that can overcome drug resistant bacteria
A new class of antibiotics not only shows promise against a broad array of bacterial infections but can also evade the dreaded resistance that has been rendering our current generation of first-line antibiotics ineffective.
-
NewsLong-acting HIV treatment demonstrates efficacy in people with challenges taking daily medicine as prescribed
Long-acting antiretroviral therapy (ART) with cabotegravir and rilpivirine was superior in suppressing HIV replication compared to daily oral ART in people who had been unable to maintain viral suppression through an oral daily regimen, according to interim data from a randomized trial. Source: NIAID Colorized transmission electron micrograph ...
-
NewsLow-cost microbe can speed biological discovery
Researchers have created a new version of a microbe to compete economically with E. coli – a bacteria commonly used as a research tool due to its ability to synthesize proteins – to conduct low-cost and scalable synthetic biological experiments.
-
News£1.8m grant to engineer microbial cell factories
A team of academics from Aston University and the University of Warwick has secured a £1.8m grant to engineer microbial cell factories to produce membrane proteins which will support future drug screening and sustainable chemical production.
-
NewsNew molecular toolkit boosts useful molecule production from yeast communities
A new molcular toolkit consists of 15 different yeast strains that over-produce key cellular building blocks – amino acids and nucleotides – but lack the ability to make other building blocks.
-
NewsFlu virus variants resistant to new antiviral drug candidate lose pathogenicity, study finds
Influenza A viruses with induced resistance to a new candidate antiviral drug were found to be impaired in cell culture and weakened in animals, a new study has found.
-
NewsAiCuris and DZIF sign Collaboration and License Option Agreement
AiCuris Anti-infective Cures AG and the German Center for Infection Research (DZIF) have announced the signing of a collaboration and license option agreement.
-
NewsMutating hepatitis viruses make drug treatment more difficult
Sofosbuvir and Ribavirin combination therapy efficiently decreased viral RNA in blood and stool in patients with chronic HEV infection, but variants that are associated with antiviral resistance emerged during treatment.
-
NewsFungus yields different pathway to the same pharmaceutically important substance
Researchers analyze a fungal biosynthetic pathway and discover a capable enzyme.
-
NewsScientists identify natural PLA2 inhibitor from marine fungus Aspergillus sp. c1
The identified marine fungus metabolite HN-001 ameliorates lipotoxicity by suppressing IRE-1α/XBP-1s axis and JNK pathway for MAFLD treatment with PLA2 as an upstream target.
-
NewsCollaborative infectious disease research takes aim at bystander cells
Researchers examining disease infection in bystander cells were granted nearly $500,000 from the Chan Zuckerberg Initiative to advance their work.
-
NewsNovo Nordisk Foundation partners with CARB-X to fight drug-resistant infections
The Novo Nordisk Foundation is committing up to $25 million to support the early-stage development of innovative tools to prevent, diagnose and treat the most dangerous drug-resistant bacterial infections. The three-year grant will go to the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), the leading global non-profit public-private partnership in this ...
-
NewsNew approach could address antibiotic resistance to Mycobacterium abscessus
Scientists have designed new versions of the drug spectinomycin that overcome efflux, the main mechanism driving resistance.
-
NewsCalibr announces license agreement with Gilead to develop long-acting HIV antiviral agent
Long-acting combination HIV regimens have the potential to transform the future of coordinated HIV clinical care
-
News Study demonstrates potency of synthetic antibiotic against serious chronic infections
A new synthetic antibiotic is shown to be more effective than established drugs against ‘superbugs’ such as MRSA, a new study shows.
-
News“Honey, I shrunk the cookbook” – new approach to vaccine development
Bioinformaticians have presented a method for identifying epitopes that promise safe immunisation across the broadest possible population group.
-
NewsResearchers use AI to identify a new class of antibiotic candidates
Using deep learning, researchers have discovered a class of compounds that can kill methicillin-resistant Staphylococcus aureus (MRSA) grown in a lab dish and in two mouse models of MRSA infection.
-
NewsAntibiotic substance isolated from bacteria in the human nose
Researchers have discovered a novel antibiotic substance from the human nose that can be used against pathogenic bacteria. Epifadin is produced from specific strains of the bacterial species Staphylococcus epidermidis.
